Literature DB >> 24913506

Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities.

Mohamed E Salama1, Shouying Du, Olga Efimova, Nahla M Heikal, Erik Wendlandt, Reha M Toydemir, Sarah South, Sherrie L Perkins, Jerry W Hussong, Fenghuang Zhan.   

Abstract

Little is known about aberrant antigen expression patterns and their association with cytogenetic aberrations in multiple myeloma (MM). We examined the correlation between flow cytometry and florescence in situ hybridization (FISH) in 167 marrow specimens with MM. Gene expression profiling of CD56, CD117, CD52 and CD20 mRNA in plasma cells (PCs) from patients treated on Total Therapy 2 and Total Therapy 3 trials were also evaluated. Higher expression of CD56 and CD117 was associated with hyperdiploidy. High CD52 mRNA expression was associated with c-MAF and FGFR3 subgroups. Higher expression of CD56 mRNA, but lower Kit expression, were noted in association with FGFR3. In contrast, the c-MAF subgroup showed high Kit expression but lacked NCAM mRNA expression. CKS1B amplification showed positive correlation with CD52 (p=0.0065) but negative correlation with CD20 (p=0.0207). These findings indicate that phenotypic differences in MM are associated with distinct genetic subgroups, which potentially has important diagnostic and prognostic value.

Entities:  

Keywords:  Cytogenetics; molecular genetics; myeloma

Mesh:

Substances:

Year:  2014        PMID: 24913506      PMCID: PMC4408538          DOI: 10.3109/10428194.2014.931951

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  21 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.

Authors:  I Van Riet; M De Waele; L Remels; P Lacor; R Schots; B Van Camp
Journal:  Br J Haematol       Date:  1991-11       Impact factor: 6.998

3.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Authors:  Fenghuang Zhan; Bart Barlogie; Varant Arzoumanian; Yongsheng Huang; David R Williams; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Maurizio Zangari; Madhav Dhodapkar; John D Shaughnessy
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

Review 4.  The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Authors:  Régis Bataille; Gaëtan Jégo; Nelly Robillard; Sophie Barillé-Nion; Jean-Luc Harousseau; Philippe Moreau; Martine Amiot; Catherine Pellat-Deceunynck
Journal:  Haematologica       Date:  2006-09       Impact factor: 9.941

5.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.

Authors:  T R Golub; D K Slonim; P Tamayo; C Huard; M Gaasenbeek; J P Mesirov; H Coller; M L Loh; J R Downing; M A Caligiuri; C D Bloomfield; E S Lander
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

6.  Genetic abnormalities and patterns of antigenic expression in multiple myeloma.

Authors:  Gema Mateo; Mariana Castellanos; Ana Rasillo; Norma C Gutiérrez; Ma Angeles Montalbán; Ma Luisa Martín; Jesús Ma Hernández; Ma Consuelo López-Berges; Laura Montejano; Joan Bladé; Ma Victoria Mateos; Anna Sureda; Javier de la Rubia; Joaquín Díaz-Mediavilla; Atanasio Pandiella; Juan José Lahuerta; Alberto Orfao; Jesús F San Miguel
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

7.  Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.

Authors:  C S Debes-Marun; G W Dewald; S Bryant; E Picken; R Santana-Dávila; N González-Paz; J M Winkler; R A Kyle; M A Gertz; T E Witzig; A Dispenzieri; M Q Lacy; S V Rajkumar; J A Lust; P R Greipp; R Fonseca
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

8.  Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.

Authors:  Bart Barlogie; Elias Anaissie; Frits van Rhee; Jeffrey Haessler; Klaus Hollmig; Mauricio Pineda-Roman; Michele Cottler-Fox; Abid Mohiuddin; Yazan Alsayed; Guido Tricot; Vanessa Bolejack; Maurizio Zangari; Joshua Epstein; Nathan Petty; Douglas Steward; Bonnie Jenkins; Jennifer Gurley; Ellen Sullivan; John Crowley; John D Shaughnessy
Journal:  Br J Haematol       Date:  2007-07       Impact factor: 6.998

9.  Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.

Authors:  Gema Mateo; M Angeles Montalbán; Maria-Belén Vidriales; Juan J Lahuerta; Maria V Mateos; Norma Gutiérrez; Laura Rosiñol; Laura Montejano; Joan Bladé; Rafael Martínez; Javier de la Rubia; Joaquín Diaz-Mediavilla; Anna Sureda; José M Ribera; José M Ojanguren; Felipe de Arriba; Luis Palomera; Maria J Terol; Alberto Orfao; Jesús F San Miguel
Journal:  J Clin Oncol       Date:  2008-04-28       Impact factor: 44.544

10.  An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

Authors:  Wei Xiong; Xiaosong Wu; Sarah Starnes; Sarah K Johnson; Jeff Haessler; Siqing Wang; Lijuan Chen; Bart Barlogie; John D Shaughnessy; Fenghuang Zhan
Journal:  Blood       Date:  2008-03-12       Impact factor: 22.113

View more
  2 in total

1.  Immunophenotypic Characterization and Ploidy Analysis of Neoplastic Plasma Cells by Multiparametric Flow Cytometry.

Authors:  R Gupta; P Gupta; K Rahman; S Biswas; D Chandra; M K Singh; M K Sarkar; A Gupta; S Nityanand
Journal:  Indian J Hematol Blood Transfus       Date:  2021-08-10       Impact factor: 0.915

2.  CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma.

Authors:  Elina Alaterre; Sebastien Raimbault; Hartmut Goldschmidt; Salahedine Bouhya; Guilhem Requirand; Nicolas Robert; Stéphanie Boireau; Anja Seckinger; Dirk Hose; Bernard Klein; Jérôme Moreaux
Journal:  Oncotarget       Date:  2017-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.